Stem Cell Therapy for Lupus: What the First Placebo-Controlled MSC Trial Found

In 2010, two small studies out of China reported something that got the attention of lupus doctors everywhere.

Sixteen people with severe lupus got an IV infusion of umbilical cord mesenchymal stem cells. In a second study, 15 people got donor MSCs. Disease activity scores dropped. Protein in the urine dropped. The authors described improvement in every patient.

Sounds like the end of the story. It wasn't. Neither study had a control group. Nobody was blinded. And lupus is a disease that flares and settles on its own, so a drop in disease activity after any treatment is hard to read.

Then in 2017, a small Chinese trial that did use a placebo found no added benefit at all. So which is it?

This month we got the best answer so far. It is more interesting than either side's headline.

What Is Lupus, and Why Do Researchers Think Stem Cells Could Help?

Lupus is an autoimmune disease. The immune system makes antibodies against the body's own tissue. It can hit the skin, joints, blood, kidneys, heart, lungs, and brain. Most people with lupus are women, and it tends to be more severe in Black, Hispanic, and Asian patients.

Treatment today is mostly about holding the immune system down. Hydroxychloroquine, steroids, and immune-suppressing drugs are the backbone. Two targeted biologic drugs, belimumab and anifrolumab, are FDA-approved for lupus. For many people this works well enough. For some, the disease stays active no matter what they try. That group is called "refractory," and it is who this research is about.

Mesenchymal stem cells, or MSCs, are cells found in bone marrow, fat, and umbilical cord tissue. In lab studies they release signals that dampen overactive immune cells and encourage regulatory T cells, the immune system's brakes. That is the theory behind using them in lupus. They are not being tested to rebuild tissue here. They are being tested as an immune modulator.

Theory is cheap. The question is what happens in people, compared with a fair control.

What Did the Early Lupus Stem Cell Studies Show?

Here is the short history, in order:

• 2010, open-label (China): Liang and colleagues gave donor MSCs to 15 patients with persistently active lupus. At 12 months, average disease activity scores (SLEDAI) fell from about 12.2 to 3.2, and urine protein fell too. A separate 16-patient study by Sun and colleagues used umbilical cord MSCs and reported similar improvement. No control group in either.
• 2017, randomized and placebo-controlled (China): Deng and colleagues randomized 18 patients with lupus kidney disease to cord MSCs or placebo, both on top of strong standard immune suppression. Remission happened in 75% (9 of 12) on MSCs and 83% (5 of 6) on placebo. One MSC patient died of severe pneumonia. The trial was stopped early because it was clear it would not show a benefit.

So the early, uncontrolled results looked great. The first small controlled test found nothing extra. That pattern shows up again and again in medicine. It is exactly why a bigger, well-run trial was needed.

What Was the MiSLE Trial?

MiSLE stands for Mesenchymal Stem Cells in SLE. It was led by Gary Gilkeson and Diane Kamen at the Medical University of South Carolina, with investigators from Cedars-Sinai, Emory, Northwestern, UC San Diego, UNC, the University of Rochester, the Feinstein Institutes, and the Oklahoma Medical Research Foundation. The registry lists it as a Phase 2, randomized, double-blind trial that started in November 2018 and is now complete.

• Who: adults with active lupus that had not responded to standard therapy. 89% were women and 36% were Black.
• What: one IV infusion of donor umbilical cord-derived MSCs, or a placebo infusion of the same salt solution without cells. Everyone stayed on their usual treatment.
• Two doses, tested in sequence: 1 million cells per kilogram of body weight first. After a safety review, 5 million cells per kilogram. For a 154-pound (70 kg) adult, that is about 70 million and 350 million cells.
• Size: 87 randomized, 81 infused (54 MSC, 27 placebo).
• Main goal: response at week 24 on a standard lupus scale called SRI-4. To count as a responder, a patient had to improve their disease activity score by at least 4 points, with no new major organ flares, no worsening in their doctor's overall rating, prednisone at 10 mg a day or less from week 20, and no new or increased immune-suppressing drugs.

That last point matters. You could not "respond" just because your doctor raised your steroids. It is a strict bar, which is the point.

What Did the MiSLE Trial Find?

Start with the main result, because that is the one the trial was designed to answer.

At week 24, 38.9% of patients on MSCs (21 of 54) were responders, vs 23.1% on placebo (6 of 26). That gap was not statistically significant (p = 0.156). In plain words: the trial missed its primary goal.

Now the secondary findings, which are why researchers are not walking away:

• Dose seemed to matter. In the high-dose group, 48.1% responded (odds ratio 3.37, p = 0.054). In the low-dose group, 29.6% responded (p = 0.685).
• Earlier separation. In the high-dose cohort, counting only patients with data at each visit, 50.0% responded at week 12 vs 8.3% on placebo. The gap was nominally significant through week 20, then narrowed by week 24 (55.6% vs 27.3%, p = 0.097).
• Per-protocol results. Among patients who followed the protocol as planned, 53.8% responded on MSCs vs 30.0% on placebo (p = 0.065). In the high-dose cohort, 68.4% vs 42.9%.

Was It Safe?

Through week 52, overall side effect rates were similar between groups:

One detail deserves a straight mention. In the first, low-dose cohort, serious adverse events were more common with MSCs than with placebo (44.4% vs 0%, p = 0.003). In the high-dose cohort it went the other way (11.1% vs 30.8%, not significant). The abstract does not explain the low-dose imbalance, and the full paper should. Remember these are people with active, hard-to-control lupus, so a lot of side effects in both arms is expected.

How Does This Compare With Other Cell Therapies for Lupus?

MSCs are not the only cell-based approach in lupus research. Here is how the main ones stack up:

Transplant and CAR T are big, hospital-based procedures with chemotherapy and real risk. We covered how stem cell transplant is being studied in another autoimmune disease in stem cell transplant for MS. MSC infusion is a much lighter procedure. That is part of why researchers want to know if it works. Lighter only matters if it actually helps.

What Are the Honest Objections?

• The main goal was missed. You will see some people quote the 48% number without saying that. Don't let them.
• Subgroup findings often shrink. When a trial misses overall and one dose looks better, the next trial frequently finds a smaller effect. Sometimes it holds up. That is what a confirmatory trial is for.
• One infusion, fading effect. Even in the best-looking group, the gap narrowed by six months.
• Placebo response is real. 23% of people on a salt-water infusion met a strict response bar. Lupus moves on its own, and good trial care helps.
• Safety is still being learned. 81 people is not enough to rule out uncommon risks. See our overview of stem cell therapy side effects.

We have seen this pattern before. In the laromestrocel frailty trial, an MSC product missed its main time point but showed a later signal, and a follow-up study is being planned. Promising and proven are different words for a reason.

Does This Research Apply to Other Stem Cell Products?

No. Trial results belong to the exact product that was tested.

The MiSLE cells were made by a specific lab, under a specific process, at doses of 1 or 5 million cells per kilogram, given once by IV to people with active lupus who stayed on their medicines. Change the maker, the tissue, the processing, the dose, or the patients, and you have a different product with its own unknowns.

It also matters how the product is regulated. In the U.S., an MSC product being tested to treat a disease is studied as an investigational product in a registered trial. The only FDA-approved MSC therapy so far is for a different disease entirely, which we explained in Ryoncil, the first FDA-approved MSC therapy. For the bigger picture, see stem cell therapy and FDA approval.

Where The Stem Cell Club Fits

Plain answer: we are not part of the MiSLE trial and have no connection to the researchers or the lab that made those cells.

We offer umbilical cord Wharton's Jelly MSC options sourced from an FDA-registered U.S. lab. Those are a different product from the one tested in this trial, made by a different lab, at different doses. Lab registration covers facility and manufacturing standards. It is not FDA approval of a therapy. Our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease, including lupus, and the results above do not apply to them.

If you have lupus, your rheumatologist is your most important partner. Never stop or change lupus medicines on your own. Stopping lupus medicines without a plan can lead to flares. If you want to explore research, search ClinicalTrials.gov for "lupus" and bring what you find to your rheumatologist.

Questions to Ask Before You Believe Any "Stem Cells for Lupus" Claim

• Was there a placebo group? Lupus flares and settles on its own.
• Did the trial meet its main goal? Or is someone quoting a subgroup?
• Is it the same product? Same source, same maker, same dose?
• How long did the effect last? Six months is different from six weeks.
• Was it published in full? Or only as a press release or conference abstract?
• What happens to my current treatment? Any honest provider will tell you to keep your rheumatologist in the loop.

We keep a longer checklist here: questions to ask any stem cell clinic.

Frequently Asked Questions